688581.SHG Hangzhou AGS MedTech Co. Ltd. A
- Market cap
- CNY 4.15B
- P/E
- 21.3x
- P/B
- 1.55x
- ROE
- 9.3%
- Dividend yield
- 2.68%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688581.SHG undervalued?
Graham number688581.SHG trades 21.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hangzhou AGS MedTech Co. Ltd. A fundamental analysis
No fundamental analysis for Hangzhou AGS MedTech Co. Ltd. A yet.
Hangzhou AGS MedTech Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hangzhou AGS MedTech Co. Ltd. A
Hangzhou AGS MedTech Co., Ltd., together with its subsidiaries, engages in the research, development, production, sale, and service of endoscopic minimally invasive diagnostic and therapeutic devices in China and internationally. The company offers hemostasis products, including hemoclips and traction clips; biopsy products, such as disposable biopsy, swinging biopsy, and grasping forceps; and EMR products comprising polypectomy snares and disposable sclerotherapy needles. I…
Full company profileHangzhou AGS MedTech Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hangzhou AGS MedTech Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 305M | 371M | 509M | 637M | 594M | 603M |
| Gross Profit | 305M | 253M | 361M | 459M | 422M | 431M |
| Operating Income | 305M | 160M | 227M | 288M | 224M | 238M |
| EBITDA | - | 172M | 258M | 353M | 276M | 278M |
| Net Income | 105M | 145M | 217M | 293M | 222M | 236M |
| EPS | 1.72 | 2.39 | 2.68 | 3.62 | 2.73 | 2.91 |
| Balance Sheet | ||||||
| Total Assets | 342M | 473M | 2.33B | 2.55B | 2.68B | 2.73B |
| Total Liabilities | 70.5M | 91.6M | 123M | 153M | 160M | 182M |
| Shareholders' Equity | 0.00 | 382M | 2.21B | 2.40B | 2.52B | 2.55B |
| Cash & Short-term Investments | 205M | 213M | 1.95B | 1.03B | 1.18B | 1.44B |
| Cash Flow | ||||||
| Operating Cash Flow | 118M | 156M | 221M | 316M | 151M | - |
| Capital Expenditure | 15.7M | 60.1M | 51.6M | 49.6M | 63.5M | 60.9M |
| Free Cash Flow | 118M | 96.3M | 170M | 266M | 87.7M | 226M |
| Ratios | ||||||
| ROE | - | 38.0% | 9.8% | 12.2% | 8.8% | 9.3% |
| ROA | 30.6% | 30.6% | 9.3% | 11.5% | 8.3% | 8.7% |
| Net Profit Margin | 34.3% | 39.1% | 42.7% | 46.1% | 37.3% | 39.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Hangzhou AGS MedTech Co. Ltd. A dividends
- Dividend yield
- 2.68%
- Forward dividend
- 1.04 CNY
- Payout ratio
- 50.2%
- Ex-dividend date
- Jun 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 111M | 1.37 | 50.2% |
| 2024 | CNY 83.3M | 1.03 | 28.4% |
| 2023 | CNY 44.0M | 0.54 | 20.2% |
| 2022 | CNY 36.0M | 0.59 | 24.8% |
| 2021 | CNY 49.0M | 0.81 | 46.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 21, 2024.
Who owns Hangzhou AGS MedTech Co. Ltd. A
- Insiders 66.88%
- Institutions 6.99%
- Public & others 26.13%
- Shares outstanding 80.7M
- Free float 28.6M
Hangzhou AGS MedTech Co. Ltd. A company profile
- Company name
- Hangzhou AGS MedTech Co. Ltd. A
- Ticker
- 688581.SHG
- ISIN
- CNE100005ZF0
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 807
- Fiscal year end
- December
- Address
- No. 389, Xingzhong Road, Hangzhou, China, 311199
- Phone
- 86 571 8767 1223
- Website
- bioags.com
About Hangzhou AGS MedTech Co. Ltd. A
Hangzhou AGS MedTech Co., Ltd., together with its subsidiaries, engages in the research, development, production, sale, and service of endoscopic minimally invasive diagnostic and therapeutic devices in China and internationally. The company offers hemostasis products, including hemoclips and traction clips; biopsy products, such as disposable biopsy, swinging biopsy, and grasping forceps; and EMR products comprising polypectomy snares and disposable sclerotherapy needles. It also provides ESD products, which include electrosurgical generators, endoscopic C02 regulation units, endoscopic water pumps, single use electrosurgical knife combination, and bipolar coagulation forceps; ERCP products, such as disposable guide wires, disposable stone extraction baskets, stone retrieval balloons, and sphincterotome; and accessories, including disposable endoscope cleaning brushes. The company was incorporated in 2010 and is headquartered in Hangzhou, China.
Hangzhou AGS MedTech Co. Ltd. A management
6- Mr. Cheng ZhangChairman & GM · born 1970
- Mr. Yueyuan ShengDeputy General Manager · born 1977
- Mr. Juncan ChenCFO & Chief Accounting Officer · born 1981
- Mr. Qinhua ZhangBoard Secretary · born 1980
- Mr. Peng LiCore Technical Personnel · born 1987
- Mr. Chun Qi HanDeputy General Manager · born 1983